{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:44:42Z","timestamp":1762915482255,"version":"3.45.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.7759\/cureus.96616","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:27:47Z","timestamp":1762914467000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparing the Long-Term Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Versus Mineralocorticoid Receptor Antagonists as Add-On Therapies in the Management of Heart Failure: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Varghese","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit H","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinni","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revanth","family":"MP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anagha","family":"Vasant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haroon","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","volume":"27","author":"Bozkurt B","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et al.. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021, 27:387-413. 10.1016\/j.cardfail.2021.01.022","journal-title":"J Card Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"8","author":"Lippi G","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. Ann Transl Med. 2020, 8:797. 10.21037\/amj.2020.03.03","journal-title":"Ann Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen A","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020, 22:1342-56. 10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese G","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017, 3:7-11. 10.15420\/cfr.2016:25:2","journal-title":"Card Fail Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual global economic burden of heart failure","volume":"171","author":"Cook C","year":"2014","unstructured":"Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014, 171:368-76. 10.1016\/j.ijcard.2013.12.028","journal-title":"Int J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink HJ","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016, 134:752-72. 10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer M","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020, 43:508-11. 10.2337\/dci19-0074","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad F","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al.. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364:11-21. 10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif ME","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al.. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021, 27:1954-60. 10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al.. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021, 384:117-28. 10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon SD","year":"2024","unstructured":"Solomon SD, McMurray JJ, Vaduganathan M, et al.. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024, 391:1475-85. 10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430160-comparing-the-long-term-effectiveness-of-sodium-glucose-cotransporter-2-inhibitors-versus-mineralocorticoid-receptor-antagonists-as-add-on-therapies-in-the-management-of-heart-failure-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:27:49Z","timestamp":1762914469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430160-comparing-the-long-term-effectiveness-of-sodium-glucose-cotransporter-2-inhibitors-versus-mineralocorticoid-receptor-antagonists-as-add-on-therapies-in-the-management-of-heart-failure-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.96616","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}